Open AccessPCOS
Author(s) -
Ayesha Tariq,
Muhammad Azeem Mir,
Saba Babar,
Rahat Akhtar
Publication year - 2018
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2018.25.04.348
Subject(s) - medicine , pioglitazone , outpatient clinic , obstetrics and gynaecology , polycystic ovary , group b , confidence interval , gynecology , diabetes mellitus , type 2 diabetes , obesity , insulin resistance , pregnancy , endocrinology , biology , genetics
Objectives: The objective is to compare the efficacy of Pioglitazone andMetformin for ovulation in patients of polycystic ovarian syndrome. Study Design: Randomizedcontrol trial. Setting: Department of Obstetrics and Gynecology, Nishtar Hospital Multan. Period:January 2017 to June 2017. Methodology: Total number of 66 patients was recruited for thisstudy. These patients were admitted through or outpatient department. Group A and Group B,33 patients each. In Group-A patients received metformin while in Group B pioglitazone wasadministered. Sample size was calculated using the reference study by Chaudhry I et al (9)using sample size calculator for two proportions (power of study 80% and confidence interval95% where prevalence (P1) was 52.17% and (P2) 75%). In group-A patients, Metformin withdose of 1500 mg per day in three divided doses were given for 6 months. In group B patients,Pioglitazone 15mg was administered for 6 months. At the end of 6 months, all the patients wereevaluated for efficacy. Results: Total no. of 66 patients was included. The mean age and BMIof the patients was 29.35±4.01 years and 29.74±2.75 kg/m2 respectively. The age distributionnoted as 66.7% (n=44) patients between 18-30 years and 33.3% (n=22) between 31-37 years.BMI distribution observed as 45.5% (n=30) patients between 24-29 kg/m2 and 54.5% (n=36)patients between 30-34 kg/m2. These 100% (n=66) patients were divided into 2 groups equally,33 in each, i.e. group A and group B. The mean age and BMI of the patients of group Awas 29.42±4.32 years and 29.87±2.58 kg/m2 respectively, while the mean age and BMI ofthe patients of group B was 29.27±3.75 years and 29.60±2.94 kg/m2 respectively. Ovulationwas noted as 42.4% (n=14) and 45.5% (=15) for groups A and B respectively. No associationwas found between efficacy and ovulation (p=0.849). Efficacy was notes as 69.7% (n=23) and72.7% (n=24) for group A and group B respectively. No difference was found between efficacyand groups i.e. between pioglitazone and metformin for ovulation in patients of polycystic ovarysyndrome (p=0.786). Similarly, no association was found between efficacy with age (p=0.442)and BMI (p=0.728), after applying the chi-square. Conclusion: This study concludes thatPioglitazone is as much effective as metformin for ovulation induction in women with PCOS.